The AI data analytics group, which specialises in aiding neuroscience clinical drug development, will showcase its work in classifying sufferers of the disease.
It will also outline advances in measuring brain volume change and the work it has done using diffusion MRI analysis to assess the degenerative condition.
The posters will be displayed in the Indigo Foyer on Thursday (December 5) at the Hilton Bayfront, San Diego, which is hosting the 2019 Clinical Trials on Alzheimer's Disease Congress (CTAD).
IXICO’s chief products officer, Alison Howie, said: "We are delighted to be presenting three abstracts at this year's CTAD Congress, demonstrating IXICO's expertise in advancing data analytics to deliver intelligent insights which are vital in ensuring the successful progression of clinical trials.
“IXICO's key mission is the development of data analytics to speed the advancement of effective treatments for neurodegenerative diseases, like Alzheimer's disease, that tragically affect so many patients worldwide."
For more details on the posters and information on the event, click here.